RU2018136877A - Способы раннего вмешательства для профилактики или улучшения состояния токсичности - Google Patents

Способы раннего вмешательства для профилактики или улучшения состояния токсичности Download PDF

Info

Publication number
RU2018136877A
RU2018136877A RU2018136877A RU2018136877A RU2018136877A RU 2018136877 A RU2018136877 A RU 2018136877A RU 2018136877 A RU2018136877 A RU 2018136877A RU 2018136877 A RU2018136877 A RU 2018136877A RU 2018136877 A RU2018136877 A RU 2018136877A
Authority
RU
Russia
Prior art keywords
therapy
treatment
individual
paragraphs
crs
Prior art date
Application number
RU2018136877A
Other languages
English (en)
Russian (ru)
Inventor
Майкл ДЖЕНСЕН
Ребекка ГАРДНЕР
Original Assignee
СИЭТЛ ЧИЛДРЕН'С ХОСПИТАЛ (ДиБиЭй СИЭТЛ ЧИЛДРЕН'С РИСЕРЧ ИНСТИТЬЮТ)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58609964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2018136877(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by СИЭТЛ ЧИЛДРЕН'С ХОСПИТАЛ (ДиБиЭй СИЭТЛ ЧИЛДРЕН'С РИСЕРЧ ИНСТИТЬЮТ) filed Critical СИЭТЛ ЧИЛДРЕН'С ХОСПИТАЛ (ДиБиЭй СИЭТЛ ЧИЛДРЕН'С РИСЕРЧ ИНСТИТЬЮТ)
Publication of RU2018136877A publication Critical patent/RU2018136877A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
RU2018136877A 2016-03-22 2017-03-22 Способы раннего вмешательства для профилактики или улучшения состояния токсичности RU2018136877A (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662311906P 2016-03-22 2016-03-22
US62/311,906 2016-03-22
US201662417287P 2016-11-03 2016-11-03
US62/417,287 2016-11-03
US201662429722P 2016-12-02 2016-12-02
US62/429,722 2016-12-02
PCT/US2017/023676 WO2017165571A1 (en) 2016-03-22 2017-03-22 Early intervention methods to prevent or ameliorate toxicity

Publications (1)

Publication Number Publication Date
RU2018136877A true RU2018136877A (ru) 2020-04-22

Family

ID=58609964

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018136877A RU2018136877A (ru) 2016-03-22 2017-03-22 Способы раннего вмешательства для профилактики или улучшения состояния токсичности

Country Status (13)

Country Link
US (5) US11518814B2 (enExample)
EP (3) EP4545143A3 (enExample)
JP (3) JP7048571B2 (enExample)
KR (1) KR20190021200A (enExample)
CN (1) CN109476743A (enExample)
AU (2) AU2017238218B2 (enExample)
BR (1) BR112018069251A2 (enExample)
CA (1) CA3018588A1 (enExample)
ES (1) ES2907557T3 (enExample)
MA (2) MA71266A (enExample)
MX (1) MX2018011480A (enExample)
RU (1) RU2018136877A (enExample)
WO (1) WO2017165571A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CN117427091A (zh) 2014-10-20 2024-01-23 朱诺治疗学股份有限公司 用于过继细胞治疗中的给药的组合物和方法
MA43377A (fr) 2015-12-04 2021-05-19 Hutchinson Fred Cancer Res Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
RU2018136877A (ru) 2016-03-22 2020-04-22 СИЭТЛ ЧИЛДРЕН'С ХОСПИТАЛ (ДиБиЭй СИЭТЛ ЧИЛДРЕН'С РИСЕРЧ ИНСТИТЬЮТ) Способы раннего вмешательства для профилактики или улучшения состояния токсичности
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
US20200078400A1 (en) * 2016-12-03 2020-03-12 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CA3053539A1 (en) 2017-02-27 2018-08-30 Juno Therapeutics, Inc. Compositions, articles of manufacture and methods related to dosing in cell therapy
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
KR20200116081A (ko) * 2017-12-01 2020-10-08 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포의 투약 및 조절 방법
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
WO2019156795A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
UA127519C2 (uk) * 2018-02-16 2023-09-20 Інсайт Корпорейшн Інгібітори шляху jak1, призначені для лікування порушень, пов'язаних із цитокінами
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
US20210046159A1 (en) * 2018-03-09 2021-02-18 Ospedale San Raffaele S.R.L. Il-1 antagonist and toxicity induced by cell therapy
KR20210013013A (ko) * 2018-03-09 2021-02-03 카르스젠 테라퓨틱스 리미티드 종양 치료 방법 및 조성물
US20210263045A1 (en) * 2018-04-06 2021-08-26 The Board Of Regents Of The University Of Texas System Prediction and treatment of immunotherapeutic toxicity
WO2021028469A1 (en) * 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021030526A1 (en) * 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
KR20220163940A (ko) 2020-02-04 2022-12-12 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 항-디니트로페놀 키메라 항원 수용체
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
US20230366893A1 (en) * 2020-09-29 2023-11-16 Washington University Methods to determine risk of neurotoxicity
JP2023552452A (ja) 2020-12-08 2023-12-15 インサイト・コーポレイション 白斑治療用のｊａｋ１経路阻害薬
EP4696710A3 (en) 2021-05-03 2026-05-06 Incyte Corporation Jak1 pathway inhibitors for the treatment of prurigo nodularis
WO2026092543A1 (en) * 2024-10-29 2026-05-07 Shenzhen Genocury Biotech Co., Ltd Methods and compositions of prophylactic therapy for preventing crs

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US265209A (en) 1882-09-26 Automatic feeder for perforators
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
CA2147466A1 (en) 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
US6080407A (en) * 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
EP2032167B1 (en) * 2006-06-22 2016-08-17 CellAct Pharma GmbH A novel target in the treatment of cytokine release syndrome
PL2856876T3 (pl) 2007-03-30 2018-06-29 Memorial Sloan-Kettering Cancer Center Konstytutywna ekspresja ligandów kostymulujących na limfocytach T poddanych transferowi adoptywnemu
ES2640216T3 (es) 2007-12-07 2017-11-02 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
US8822647B2 (en) 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
ES2717629T3 (es) 2009-11-03 2019-06-24 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
CN103249742B (zh) * 2010-09-16 2017-04-12 巴利奥医药股份公司 抗人肿瘤坏死因子1型受体抗体
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
US10208086B2 (en) 2011-11-11 2019-02-19 Fred Hutchinson Cancer Research Center Cyclin A1-targeted T-cell immunotherapy for cancer
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
CN107557334B (zh) 2012-05-03 2021-06-25 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
LT3338794T (lt) * 2012-07-13 2020-05-25 The Trustees Of The University Of Pennsylvania Car priešnavikinio aktyvumo toksiškumo reguliavimas
PL3824905T3 (pl) 2012-08-20 2025-05-05 Fred Hutchinson Cancer Center Sposób i kompozycje do immunoterapii komórkowej
SG11201502598SA (en) 2012-10-02 2015-05-28 Sloan Kettering Inst Cancer Compositions and methods for immunotherapy
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
CN107530376A (zh) * 2015-02-18 2018-01-02 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
WO2017035362A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
CN116334205A (zh) * 2015-09-03 2023-06-27 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
RU2018136877A (ru) 2016-03-22 2020-04-22 СИЭТЛ ЧИЛДРЕН'С ХОСПИТАЛ (ДиБиЭй СИЭТЛ ЧИЛДРЕН'С РИСЕРЧ ИНСТИТЬЮТ) Способы раннего вмешательства для профилактики или улучшения состояния токсичности
SG11201900344YA (en) 2016-07-15 2019-02-27 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor

Also Published As

Publication number Publication date
EP4015536A1 (en) 2022-06-22
US20230322937A1 (en) 2023-10-12
JP2022088489A (ja) 2022-06-14
JP2019509351A (ja) 2019-04-04
MA44486A (fr) 2019-01-30
US20190112379A1 (en) 2019-04-18
ES2907557T3 (es) 2022-04-25
AU2024205049A1 (en) 2024-08-15
EP3433276B1 (en) 2021-12-22
AU2017238218A1 (en) 2018-10-11
WO2017165571A1 (en) 2017-09-28
CA3018588A1 (en) 2017-09-28
JP7048571B2 (ja) 2022-04-05
JP7528143B2 (ja) 2024-08-05
US20230212298A1 (en) 2023-07-06
EP4545143A2 (en) 2025-04-30
US11518814B2 (en) 2022-12-06
MA71266A (fr) 2025-04-30
KR20190021200A (ko) 2019-03-05
US20240425608A1 (en) 2024-12-26
JP2024156736A (ja) 2024-11-06
EP4545143A3 (en) 2025-07-23
EP3433276A1 (en) 2019-01-30
US12098208B2 (en) 2024-09-24
CN109476743A (zh) 2019-03-15
MX2018011480A (es) 2019-03-28
BR112018069251A2 (pt) 2019-01-22
US20230091447A1 (en) 2023-03-23
AU2017238218B2 (en) 2024-05-02
US11760804B2 (en) 2023-09-19

Similar Documents

Publication Publication Date Title
AU2017238218A1 (en) Early intervention methods to prevent or ameliorate toxicity
Shao et al. Targeted treatment for erythrodermic psoriasis: rationale and recent advances
Xiao et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
Maronese et al. Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments
Chandran et al. Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: a randomized controlled trial
Izumi et al. Current clinical trials in pemphigus and pemphigoid
JP2024156736A5 (enExample)
Bagnasco et al. Anti-interleukin 5 (IL-5) and IL-5Ra biological drugs: efficacy, safety, and future perspectives in severe eosinophilic asthma
Park et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis
CN101668531B (zh) 用于治疗免疫病症的联合治疗
Cunha et al. Role of cytokines in mediating mechanical hypernociception in a model of delayed-type hypersensitivity in mice
US20150150968A1 (en) Use of cd28-specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
KR20200044889A (ko) 암 면역요법을 위해 면역 조절제와 조합된 rar 선택적 작용제
Chatila et al. Primary combined immunodeficiency resulting from defective transcription of multiple T-cell lymphokine genes.
Kulmatycki et al. Drug disease interactions: role of inflammatory mediators in depression and variability in antidepressant drug response
Ahn et al. Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate.
Loricera et al. Biologic therapy in ANCA-negative vasculitis
Paradisi et al. A new case series on etanercept treatment for toxic epidermal necrolysis
Naessens et al. CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity
Tchao et al. Ab0432 Efavaleukin alfa, a novel Il-2 mutein, selectively expands regulatory T cells in patients with SLE: final results of a phase 1b multiple ascending dose study
Wang et al. Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis
MX2007003809A (es) Agentes bloqueadores de interferon tipo i para prevencion y tratamiento de soriasis.
Lincheta et al. Long-term therapy with itolizumab is safe and effective for patients with moderate to severe psoriasis: Results from an expanded-access program
WO2022098756A1 (en) Chimeric antigen receptor cell therapy
Gobel Hypersensitivity reactions to biological drugs

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20200323